^
    Back
    Association details:
    Biomarker:CBL mutation
    Cancer:Chronic Myelomonocytic Leukemia
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Blood
    Title:

    CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1

    Published date:
    01/07/2021
    Excerpt:
    …we demonstrated in vitro and in vivo antiproliferative efficacy of dasatinib in CBL-mutant cell lines and primary CMML.
    DOI:
    10.1182/blood.2020006528